The recent disruptions in global chains have highlighted the value of securing critical medications like Ivermectin. Dependence on overseas manufacturers exposes countries to potential vulnerabilities, including delivery delays, expense fluctuations, and even trade concerns. Moving towards domestic production of Ivermectin offers a multitude of adv